Articles tagged "HLA antibodies"

2019 American Transplant Congress
Conversion from Calcineurin Inhibitors to Belatacept in Kidney Recipients with Donor-Specific Anti-HLA Antibodies and Calcineurin Inhibitor Nephrotoxicity Decreases the Pathogenicity of Donor-Specific Anti-HLA Antibodies
K. Louis¹, D. Viglietti¹, D. Pievani¹, O. Aubert¹, D. Glotz¹, C. Legendre¹, A. Zeevi², A. Loupy¹, C. Lefaucheur¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France, ²University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Switching from CNI- to Belatacept-based regimen has been associated with improved graft function in low-immunologic risk kidney recipients. We investigated the efficacy and safety…
2019 American Transplant Congress
Single Center Deceased Donor Renal Transplant (DDRTx) Outcomes in Sensitized Patients after Implementation of the Kidney Allocation System (KAS)
S. S. Patel, K. L. King, J. Kamal, E. Vasilescu, A. Husain, S. Mohan, L. E. Ratner, R. Crew
Columbia University Irving Medical Center, New York, NY
*Purpose: Introduction of KAS in 2014 prioritized access to DDRTx for highly-sensitized candidates although it was unclear whether the outcomes would be acceptable in this…
2019 American Transplant Congress
Report of 20 HLAMatchmaker Eplets Present on Denatured Class I HLA Molecules
R. de Marco¹, A. C. Lima², N. F. Pereira², M. Gerbase-DeLima¹
¹Immunogenetics Institute, AFIP, Sao Paulo, SP, Brazil, ²Immunogenetics Laboratory, Universidade Federal do Paraná, Curitiba, PR, Brazil
*Purpose: The purpose of this report is to describe 20 class I HLA eplets, herein called FakEplets, present on denatured HLA molecules.*Methods: The study included…
2019 American Transplant Congress
Clazakizumab as an Agent to Reduce Donor Specific HLA Antibodies and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation
S. C. Jordan¹, N. Ammerman¹, M. Toyoda², E. Huang¹, C. C. Nast³, A. Peng¹, S. Sethi¹, R. Najjar¹, I. Kim¹, K. Lim¹, J. Choi¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Lab, Cedars-Sinai Medical Ctr, Los Angeles, CA, ³Department of Pathology, Cedars-Sinai Medical Ctr, Los Angeles, CA
*Purpose: Highly sensitized (HS) patients are at an increased risk for chronic antibody mediated rejection (cABMR) and graft loss due to persistent, deleterious DSA production.…
2019 American Transplant Congress
Long Term Outcomes in Kidney Transplant Recipients Receiving Everolimus (EVR) or Mycophenolate (MPS) in Combination with Tacrolimus (TAC)
K. Ficher, C. Rosso Felipe, Y. Cardoso Dreige, K. Linhares, A. Ferreira Brígido, S. Stopa, L. Viana, M. Cristelli, P. Gessolo Lins, W. Aguiar, H. Proença, R. Marco, M. Gerbase de Lima, H. Tedesco Silva Junior, J. Medina Pestana
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: Detailed long-term data comparing the use of EVR or MPS in kidney transplant recipients receiving TAC is lacking.*Methods: This is a 5-years extension analysis…
2019 American Transplant Congress
Improving Pre-Kidney Transplantion Laboratory Utilization in an Era of Increasing Waitlist Size
G. K. Mahowald¹, B. Kimball², N. Elias², E. Heher³, T. Girouard¹, S. L. Saidman¹, V. Pattanayak¹
¹Pathology, Massachusetts General Hospital, Boston, MA, ²Transplant Surgery, Massachusetts General Hospital, Boston, MA, ³Nephrology, Massachusetts General Hospital, Boston, MA
*Purpose: Beginning on March 25, 2015, our institution’s kidney transplant program has implemented a “readiness” protocol, whereby patients are listed after limited workup and comprehensive…
2019 American Transplant Congress
Comparing Antibody-Mediated Rejection with or without Detectable DSA: Similar Pathology and Similar Poor Prognosis
G. Einecke¹, J. Reeve², P. F. Halloran³
¹Dpt. of Nephrology, Hannover Medical School, Hannover, Germany, ²Dpt. of Laboratory Medicine and Pathology and Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada, ³Dpt. of Nephrology and Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada
*Purpose: Banff guidelines require the detection of donor-specific antibodies (DSA) in addition to microvascular inflammation (MVI) for a diagnosis of antibody-mediated rejection (ABMR), but MVI…
2019 American Transplant Congress
Impact of HLA-DR Matching on HLA-DQ Matching Status and the Development of Anti-HLA-DQ De Novo DSA under Calcineurin Inhibitor or Belatacept Immunosuppression
V. Jucaud¹, H. Gebel², R. Bray², M. Polinsky³, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Emory University, Atlanta, GA, ³Bristol-Myers Squibb, Princeton, NJ
*Purpose: De novo donor-specific HLA antibodies (dnDSA) that develop after kidney transplantation target more frequently allo-HLA-DQ antigens in comparison to other allo-HLA antigens. Yet, organ…
2019 American Transplant Congress
Endothelial Cells Do Not Regulate Expression of CD46, CD55 and CD59 in the Presence of Anti-HLA Class I and 11 Antibodies
A. Babu¹, T. Pham², M. Hamdorf², V. Jucaud², M. Everly², S. Daga³, D. Mitchell⁴
¹Transplant Institute, Henry Ford Hospitals, Detroit, MI, ²Terasaki Research Institute, Los Angeles, CA, ³University of Warwick, Coventry, United Kingdom, ⁴Medical Sciences, University of Warwick, Coventry, United Kingdom
*Purpose: Anti-HLA antibodies, both pre-formed and de novo are associated with worse graft survival. Complement activation is an important mechanism of antibody mediated immunological injury.…
2019 American Transplant Congress
Association between Respiratory Virus Infections and the Development of De Novo HLA Donor-Specific Antibodies in Lung Transplant Recipients
M. I. Ali, J. Hata, J. Mallea, M. Elrefaei
Mayo Clinic, Jacksonville, FL
*Purpose: The detection of de novo donor-specific anti-HLA antibodies (DSA) post lung transplant have been associated with significantly increased risk for antibody-mediated rejection (AMR) and…